ReviewPulmonary medicine2019
Regulatory T Cells in Respiratory Health and Diseases.
Review in Pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Associations between vitamin D status and biomarkers linked with inflammation in patients with asthma: a systematic review and meta-analysis of interventional and observational studies.Respiratory research · 2024Pooled it
- Immunomodulatory Effects of a New Ethynylpiperidine Derivative: Enhancement of CD4Biomedicines · 2025Article
- Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025Review
- Persistence of lung structural and functional alterations at one year post-COVID-19 is associated with increased serum PD-L2 levels and altered CD4/CD8 ratio.Immunity, inflammation and disease · 2024Article
- Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT Study.Pulmonary therapy · 2024Article
- Molecular Mechanisms Responsible for the Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Lung Fibrosis.International journal of molecular sciences · 2024Review
- Immune dysregulation as a driver of bronchiolitis obliterans.Frontiers in immunology · 2024Review
- Regulatory T cells in lung disease and transplantation.Bioscience reports · 2023Review
- Host gut-derivedAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2023Article
- Distribution and chemotactic mechanism of CD4Immunity, inflammation and disease · 2023Article
- Circulating Regulatory T Cell Subsets in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2023Article
- Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.The European respiratory journal · 2022Article
- Review
- Mucosal viral infection induces a regulatory T cell activation phenotype distinct from tissue residency in mouse and human tissues.Mucosal immunology · 2022Article
- Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry.Mucosal immunology · 2022Review
- Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.Stem cell research & therapy · 2022Article
- Where do T cell subsets stand in SARS-CoV-2 infection: an update.Frontiers in cellular and infection microbiology · 2022Review
- Mannose-Modified Chitosan Poly(lactic-Polymers · 2021Article
- Airway Basal Cells, Protectors of Epithelial Walls in Health and Respiratory Diseases.Frontiers in allergy · 2021Review
- Immunomodulatory Role of Nutrients: How Can Pulmonary Dysfunctions Improve?Frontiers in nutrition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory diseases compromise the health of millions of people all over the world and are strongly linked to the immune dysfunction. CD4+FOXP3+ T regulatory cells, also known as Tregs, have a central role maintaining tissue homeostasis during immune responses. Their activity and clinical impact have been widely studied in different clinical conditions including autoimmune diseases, inflammatory conditions, and cancer, amongst others. Tregs express transcription factor forkhead box P3 (FOXP3), which allows regulation of the immune response through anti-inflammatory cytokines such as IL-10 or transforming growth factor beta (TGF-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.